Scientists behind LANCL2 target launch with phase III-ready drug
Many of the available treatments for the autoimmune conditions ulcerative colitis (UC) and Crohn’s disease come with drawbacks such as safety issues or inconvenient dosing regimens. Describing itself as a biomarker-driven immunoregulatory therapeutics company,...
NImmune Biopharma Launches with Phase III-Ready Asset Gained from Landos Biopharma
Virginia life sciences entrepreneur Josep Bassaganya-Riera’s latest company NImmune Biopharma launched with an eye on a potential New Drug Application for its Phase III-ready experimental therapeutic for ulcerative colitis. NImmune Biopharma’s lead asset...
